EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN
This paper shows the research results of the biological therapy with chimeric monoclonal antibody to tumor necrosis factor (TNF) (infliximab). 33 children aged 6 to 18 years with various forms of Crohn’s disease were enrolled in the study. Therapy duration ranged from 3 months to 1 year or more. Af...
Saved in:
Main Authors: | E. G. Tsimbalova, A. S. Potapov, M. M. Venedictova, F. F. Shavrov |
---|---|
Format: | Article |
Language: | English |
Published: |
"Paediatrician" Publishers LLC
2012-01-01
|
Series: | Вопросы современной педиатрии |
Subjects: | |
Online Access: | https://vsp.spr-journal.ru/jour/article/view/523 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn’s disease patients
by: Jiao Zheng, et al.
Published: (2025-06-01) -
Correction: Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn’s disease patients
by: Jiao Zheng, et al.
Published: (2025-07-01) -
Psoas muscle CT radiomics-based machine learning models to predict response to infliximab in patients with Crohn’s disease
by: Zhuoyan Chen, et al.
Published: (2025-12-01) -
MORPHOLOGICAL CRITERIA FOR PREDICTION OF SEVERITY OF CROHN’S DISEASE CLINICAL COURSE IN CHILDREN
by: E. N. Fedulova, et al.
Published: (2013-09-01) -
BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01)